标题
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
作者
关键词
-
出版物
Frontiers in Immunology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-11-28
DOI
10.3389/fimmu.2018.02722
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+
- (2018) F. Morandi et al. OncoImmunology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu
- (2017) L Zhang et al. Blood Cancer Journal
- Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
- (2017) Federica Costa et al. Oncotarget
- Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
- (2017) Antonella Chillemi et al. Frontiers in Immunology
- Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
- (2017) William Fumey et al. Scientific Reports
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Immuno-targeting the multifunctional CD38 using nanobody
- (2016) Ting Li et al. Scientific Reports
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
- (2015) Wen-Chi Yang et al. Biomed Research International
- α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
- (2015) Katharina Teiluf et al. Oncotarget
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity
- (2013) A. Cagnetta et al. BLOOD
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
- (2013) D. J. Green et al. CANCER RESEARCH
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- (2011) K Mihara et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse
- (2008) P. Munoz et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now